Beraprost therapy for pulmonary arterial hypertension (Q44487843)

3 December 2017

title

Beraprost therapy for pulmonary arterial hypertension (English)

1 reference

3 December 2017

Robyn J Barst

1

1 reference

3 December 2017

Michael McGoon

2

1 reference

3 December 2017

Vallerie McLaughlin

3

1 reference

3 December 2017

Victor Tapson

4

1 reference

3 December 2017

Stuart Rich

5

1 reference

3 December 2017

Lewis Rubin

6

1 reference

3 December 2017

Karlman Wasserman

7

1 reference

3 December 2017

Ronald Oudiz

8

1 reference

3 December 2017

Shelley Shapiro

9

1 reference

3 December 2017

Ivan M Robbins

10

1 reference

3 December 2017

Richard Channick

11

1 reference

3 December 2017

David Badesch

12

1 reference

3 December 2017

Barry K Rayburn

13

1 reference

3 December 2017

Robin Flinchbaugh

14

1 reference

3 December 2017

Jeff Sigman

15

1 reference

3 December 2017

Carl Arneson

16

1 reference

3 December 2017

Roger Jeffs

17

1 reference

3 December 2017

Beraprost Study Group

18

1 reference

3 December 2017

language of work or name

English

0 references

publication date

1 June 2003

1 reference

Journal of the American College of Cardiology

3 December 2017

published in

1 reference

3 December 2017

volume

41

1 reference

3 December 2017

issue

12

1 reference

3 December 2017

page(s)

2119-2125

1 reference

Primary pulmonary hypertension. A national prospective study

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900463-7

7 January 2021

Primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900463-7

7 January 2021

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900463-7

7 January 2021

Primary Pulmonary Hypertension: Improved Long-Term Effects and Survival With Continuous Intravenous Epoprostenol Infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900463-7

7 January 2021

Reduction in Pulmonary Vascular Resistance with Long-Term Epoprostenol (Prostacyclin) Therapy in Primary Pulmonary Hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900463-7

7 January 2021

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900463-7

7 January 2021

Treatment of pulmonary hypertension secondary to connective tissue diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900463-7

7 January 2021

Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900463-7

7 January 2021

Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900463-7

7 January 2021

Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900463-7

7 January 2021

Epoprostenol (prostacyclin) and pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900463-7

7 January 2021

Orally active prostacyclin analogue in primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900463-7

7 January 2021

Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900463-7

7 January 2021

Oral beraprost sodium improves exercise capacity and ventilatory efficiency in patients with primary or thromboembolic pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900463-7

7 January 2021

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900463-7

7 January 2021

Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900463-7

7 January 2021

Long-Term Treatment of Primary Pulmonary Hypertension with Aerosolized Iloprost, a Prostacyclin Analogue

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900463-7

7 January 2021

Vasodilator actions of TRK-100, a new prostaglandin I2 analogue

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900463-7

7 January 2021

Antithrombotic effect of TRK-100, a novel, stable PGI2 analogue.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900463-7

7 January 2021

The in vitro and ex vivo antiplatelet effect of TRK-100, a stable prostacyclin analog, in several species

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900463-7

7 January 2021

Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900463-7

7 January 2021

Bosentan therapy for pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900463-7

7 January 2021

10.1016/S0735-1097(03)00463-7

Identifiers

DOI

1 reference

3 December 2017

1 reference